Built To Last: The Blueprint for Sustainable Cancer Care (The Accountable Oncology Trilogy)

Built to Last: The Blueprint for Sustainable Cancer Care is the final book in a trilogy examining the economic, operational, and structural forces reshaping oncology. While the first two books explain how cancer care reached its current crossroads, Built to Last focuses on what must be constructed next. Its central argument is clear: cancer programs cannot achieve long-term sustainability by relying on reimbursement increases, procedural volume, or temporary cost reductions. They need a stronger operating model.Cancer care is among the most complex and capital-intensive areas of healthcare. Radiation oncology, medical oncology, infusion, pharmacy, imaging, surgery, diagnostics, and supportive care are frequently managed as separate departments. Each may have its own leadership, technology, financial objectives, workflows, and performance measures. Although these services care for many of the same patients, they often operate without a unified strategy.Built to Last challenges this fragmentation and presents a blueprint for creating an accountable oncology enterprise. In this model, care is organized around the complete patient journey rather than individual departments, technologies, or transactions. Clinical decisions, operational processes, financial incentives, and governance structures must work together to support appropriate care at a responsible total cost.Sustainability begins with understanding the true cost of delivering care. Oncology organizations often focus on reimbursement without fully measuring the resources required to provide services. Staffing, pharmaceuticals, equipment, software, service agreements, prior authorization, revenue-cycle functions, compliance, and other fixed costs all affect performance. Higher payment may temporarily relieve financial pressure, but it cannot correct an inefficient or poorly coordinated operating structure.Technology must also be evaluated according to value rather than novelty. Advanced equipment, artificial intelligence, automation, and data platforms can improve care, but only when they solve a defined clinical or operational problem. Technology should improve decision-making, reduce unnecessary work, expand access, and decrease variation. It should not be adopted simply because it is new, heavily marketed, or associated with higher reimbursement.A sustainable oncology enterprise also requires disciplined governance. Physicians, administrators, pharmacists, physicists, nurses, therapists, financial leaders, and revenue-cycle professionals must share responsibility for outcomes. Decisions cannot remain confined to departmental silos. Organizations need transparent data, clearly assigned accountability, and consistent measures of quality, access, capacity, cost, patient experience, and financial performance.The book also emphasizes workforce design. Cancer programs cannot remain dependent on a few individuals carrying unsustainable workloads or repeatedly rescuing broken processes. Durable organizations use standardized workflows, appropriate delegation, cross-functional teams, succession planning, and technology-supported operations to increase capacity without weakening safety or clinical oversight.Payment reform remains important, but it is not the entire solution. Bundled payments, site neutrality, value-based arrangements, and total-cost-of-care models will continue to reshape oncology. Programs that understand their costs, standardize pathways, manage utilization, and measure outcomes will be prepared to succeed.Ultimately, Built to Last calls oncology leaders to move beyond short-term survival. Sustainable cancer programs align mission with economics, innovation with evidence, and access with accountability. They are not designed merely to generate revenue today. They are built to serve patients, clinicians, and communities for decades to come.